Literature DB >> 21860020

TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms.

Angela G Fleischman1, Karl J Aichberger, Samuel B Luty, Thomas G Bumm, Curtis L Petersen, Shirin Doratotaj, Kavin B Vasudevan, Dorian H LaTocha, Fei Yang, Richard D Press, Marc M Loriaux, Heike L Pahl, Richard T Silver, Anupriya Agarwal, Thomas O'Hare, Brian J Druker, Grover C Bagby, Michael W Deininger.   

Abstract

Proinflammatory cytokines such as TNFα are elevated in patients with myeloproliferative neoplasms (MPN), but their contribution to disease pathogenesis is unknown. Here we reveal a central role for TNFα in promoting clonal dominance of JAK2(V617F) expressing cells in MPN. We show that JAK2(V617F) kinase regulates TNFα expression in cell lines and primary MPN cells and TNFα expression is correlated with JAK2(V617F) allele burden. In clonogenic assays, normal controls show reduced colony formation in the presence of TNFα while colony formation by JAK2(V617F)-positive progenitor cells is resistant or stimulated by exposure to TNFα. Ectopic JAK2(V617F) expression confers TNFα resistance to normal murine progenitor cells and overcomes inherent TNFα hypersensitivity of Fanconi anemia complementation group C deficient progenitors. Lastly, absence of TNFα limits clonal expansion and attenuates disease in a murine model of JAK2(V617F)-positive MPN. Altogether our data are consistent with a model where JAK2(V617F) promotes clonal selection by conferring TNFα resistance to a preneoplastic TNFα sensitive cell, while simultaneously generating a TNFα-rich environment. Mutations that confer resistance to environmental stem cell stressors are a recognized mechanism of clonal selection and leukemogenesis in bone marrow failure syndromes and our data suggest that this mechanism is also critical to clonal selection in MPN.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21860020      PMCID: PMC3236121          DOI: 10.1182/blood-2011-04-348144

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Signalling pathways of the TNF superfamily: a double-edged sword.

Authors:  Bharat B Aggarwal
Journal:  Nat Rev Immunol       Date:  2003-09       Impact factor: 53.106

Review 2.  The HL60 cell line: a model system for studying human myeloid cell differentiation.

Authors:  G D Birnie
Journal:  Br J Cancer Suppl       Date:  1988-12

3.  Multiple inhibitory cytokines induce deregulated progenitor growth and apoptosis in hematopoietic cells from Fac-/- mice.

Authors:  L S Haneline; H E Broxmeyer; S Cooper; G Hangoc; M Carreau; M Buchwald; D W Clapp
Journal:  Blood       Date:  1998-06-01       Impact factor: 22.113

4.  The suppressive influences of human tumor necrosis factors on bone marrow hematopoietic progenitor cells from normal donors and patients with leukemia: synergism of tumor necrosis factor and interferon-gamma.

Authors:  H E Broxmeyer; D E Williams; L Lu; S Cooper; S L Anderson; G S Beyer; R Hoffman; B Y Rubin
Journal:  J Immunol       Date:  1986-06-15       Impact factor: 5.422

5.  Effect of recombinant human tumor necrosis factor on the colony growth of human leukemia progenitor cells and normal hematopoietic progenitor cells.

Authors:  T Murase; T Hotta; H Saito; R Ohno
Journal:  Blood       Date:  1987-02       Impact factor: 22.113

6.  Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders.

Authors:  E Joanna Baxter; Linda M Scott; Peter J Campbell; Clare East; Nasios Fourouclas; Soheila Swanton; George S Vassiliou; Anthony J Bench; Elaine M Boyd; Natasha Curtin; Mike A Scott; Wendy N Erber; Anthony R Green
Journal:  Lancet       Date:  2005 Mar 19-25       Impact factor: 79.321

7.  Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells.

Authors:  Odile Beyne-Rauzy; Christian Recher; Nicole Dastugue; Cécile Demur; Géraldine Pottier; Guy Laurent; Laure Sabatier; Véronique Mansat-De Mas
Journal:  Oncogene       Date:  2004-09-30       Impact factor: 9.867

8.  Tumor necrosis factor-alpha overproduction in Fanconi's anemia.

Authors:  J C Schultz; N T Shahidi
Journal:  Am J Hematol       Date:  1993-02       Impact factor: 10.047

9.  Abnormal lymphokine production: a novel feature of the genetic disease Fanconi anemia. II. In vitro and in vivo spontaneous overproduction of tumor necrosis factor alpha.

Authors:  F Rosselli; J Sanceau; E Gluckman; J Wietzerbin; E Moustacchi
Journal:  Blood       Date:  1994-03-01       Impact factor: 22.113

10.  Self-renewal of multipotent long-term repopulating hematopoietic stem cells is negatively regulated by Fas and tumor necrosis factor receptor activation.

Authors:  D Bryder; V Ramsfjell; I Dybedal; K Theilgaard-Mönch; C M Högerkorp; J Adolfsson; O J Borge; S E Jacobsen
Journal:  J Exp Med       Date:  2001-10-01       Impact factor: 14.307

View more
  108 in total

1.  Inflammation mediated platelet hyperactivity in aging.

Authors:  Sean X Gu; Sanjana Dayal
Journal:  Ann Blood       Date:  2020-03-25

Review 2.  Preclinical models for drug selection in myeloproliferative neoplasms.

Authors:  Niccolò Bartalucci; Costanza Bogani; Alessandro M Vannucchi
Journal:  Curr Hematol Malig Rep       Date:  2013-12       Impact factor: 3.952

Review 3.  Thrombosis in Philadelphia negative classical myeloproliferative neoplasms: a narrative review on epidemiology, risk assessment, and pathophysiologic mechanisms.

Authors:  Somedeb Ball; Kyaw Zin Thein; Abhishek Maiti; Kenneth Nugent
Journal:  J Thromb Thrombolysis       Date:  2018-05       Impact factor: 2.300

Review 4.  Myeloproliferative neoplasm stem cells.

Authors:  Adam J Mead; Ann Mullally
Journal:  Blood       Date:  2017-02-03       Impact factor: 22.113

Review 5.  Management of Myelofibrosis-Related Cytopenias.

Authors:  Prithviraj Bose; Srdan Verstovsek
Journal:  Curr Hematol Malig Rep       Date:  2018-06       Impact factor: 3.952

6.  Correlations of TNF-α gene promoter polymorphisms with the risk of thymoma-associated myasthenia gravis in a northern Chinese Han population.

Authors:  H-W Yang; P Lei; Y-C Xie; Z-L Han; D Li; S-H Wang; Z-L Sun
Journal:  Cancer Gene Ther       Date:  2017-04-21       Impact factor: 5.987

7.  Intrinsic resistance to JAK2 inhibition in myelofibrosis.

Authors:  Anna Kalota; Grace R Jeschke; Martin Carroll; Elizabeth O Hexner
Journal:  Clin Cancer Res       Date:  2013-02-05       Impact factor: 12.531

8.  Defective negative regulation of Toll-like receptor signaling leads to excessive TNF-α in myeloproliferative neoplasm.

Authors:  Hew Yeng Lai; Stefan A Brooks; Brianna M Craver; Sarah J Morse; Thanh Kim Nguyen; Nahideh Haghighi; Michael R Garbati; Angela G Fleischman
Journal:  Blood Adv       Date:  2019-01-22

Review 9.  Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors.

Authors:  Minas P Economides; Srdan Verstovsek; Naveen Pemmaraju
Journal:  Curr Hematol Malig Rep       Date:  2019-10       Impact factor: 3.952

10.  JAK2-V617F-mediated signalling is dependent on lipid rafts and statins inhibit JAK2-V617F-dependent cell growth.

Authors:  Lori N Griner; Kathy L McGraw; Joseph O Johnson; Alan F List; Gary W Reuther
Journal:  Br J Haematol       Date:  2012-11-15       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.